Reporting, access, and transparency: Better infrastructure of clinical trials
Reporting, access, and transparency: Better infrastructure of clinical trials
复制标题
DOI：
10.1097/ccm.0b013e31819207bb
复制
发表时间：
2009-01-01
影响因子：
8.8
通讯作者：
Mercurio, Giovanna
中科院分区：
文献类型：
--
作者：
Antonelli, Massimo;Mercurio, Giovanna
开放获取医学科学信息和充分报道临床试验可能使研究人员和编辑认识到研究设计中的偏见，避免不必要的重复工作。不幸的是，大多数临床试验都非常昂贵，而且往往得到了可能有经济原因隐瞒或部分披露结果的行业的支持。然而，研究人员和编辑更感兴趣的是发表可以立即改变临床实践的结果，而不是负面结果，从而有助于促进发表偏见。几年前，几个国家的立法要求注册临床试验，以此作为促进信息获取和医学研究完全透明的有效手段。然而，全面的登记册没有得到法律的充分支持，特别是在欧洲，具有讽刺意味的是，欧洲的立法助长了研究的碎片化，并削弱了其竞争力和生产率。在这方面，适当的战略有助于保护学术研究的独立性，并确保医学科学的充分透明度。(《危重护理医学》2009；37[补充]：S178-S183)
Open access to information in medical science and adequate reporting of clinical trials may allow investigators and editors to recognize bias in study designs and avoid unnecessary duplication of efforts. Unfortunately, most of clinical trials are very expensive and are often supported by industries that may have financial reasons to hide or partially disclose results. However, investigators and editors have a greater interest in publishing results that can immediately change clinical practice rather than negative results, thus contributing to facilitate publication biases. Several years ago, legislation in several countries mandated the registration of clinical trials as an effective means of promoting information access and full transparency in medical research. However, comprehensive registers have not been adequately supported by law, particularly in Europe, where legislation has ironically contributed to fragmented research, and dampened its competitiveness and productivity. In this context, appropriate strategies help to protect the independence of academic research and ensure full transparency in medical science. (Crit Care Med 2009; 37[Suppl.]:S178-S183)